Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Burkitt Lymphoma 4Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1

Interventions

Azacitidine 38Cytarabine 22venetoclax 19fludarabine phosphate 18fludarabine 18Cyclophosphamide 18Peripheral Blood Stem Cell Transplantation 15Tacrolimus 14Filgrastim 13Decitabine 13Mycophenolic Acid 12Busulfan 12Whole-Body Irradiation 11Melphalan 11Methotrexate 10Cyclosporine 10Antilymphocyte Serum 8Stem Cell Transplantation 7Alemtuzumab 7decitabine and cedazuridine drug combination 6Granulocyte Colony-Stimulating Factor 6Clofarabine 6AP 1903 reagent 6Thiotepa 5Rituximab 5Idarubicin 5quizartinib 4Tretinoin 4Sirolimus 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Myelodysplastic Syndromes × merphos × Clear all
NCT04752163 2025-05-23

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
17 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡